

Resource Summary Report

Generated by [nidm-terms](#) on Sep 23, 2026

Binding Site

RRID:SCR_004051

Type: Tool

Proper Citation

Binding Site (RRID:SCR_004051)

Resource Information

URL: <http://www.thebindingsite.com/>

Proper Citation: Binding Site (RRID:SCR_004051)

Description: Company provides specialist diagnostic products to clinicians and laboratory professionals worldwide. Specialist protein company committed to research, development, manufacture and distribution of immunodiagnostic assays for global laboratory market. Specialized in antibody specificity technology, Binding Site gives clinicians and laboratory staff tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders. Binding Site manufactures wide range of products for plasma protein analysis including Freelite, Hevylite and SPAPlus.

Synonyms: The Binding Site, The Binding Site Group Ltd, Binding Site Inc, The Specialist Protein Company, Binding Site Group Ltd

Resource Type: commercial organization

Keywords: Diagnostic products, protein, diagnosis, monitoring, assay, immunodiagnostic assays

Related Condition: Cancer, Immune disorder, Multiple Myeloma, Primary immunodeficiency disease

Resource Name: Binding Site

Resource ID: SCR_004051

Alternate IDs: nlx_158482

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260919T195032+0000

Ratings and Alerts

No rating or validation information has been found for Binding Site.

No alerts have been found for Binding Site.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Verchere N, et al. (2026) The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical Application. Journal of neurochemistry, 170(4), e70423.

Harris VC, et al. (2018) Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial. Cell host & microbe, 24(2), 197.